Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 6, 2013, Pages 636-643

  Berge, Eamon M ^a   Lu, Xian ^b   Maxson, Delee ^a   Barón, Anna E ^b   Gadgeel, Shirish M ^c   Solomon, Benjamin J ^d   Doebele, Robert C ^a   Varella Garcia, Maria ^a   Camidge, D Ross ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Food Science and Human Nutrition   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

ALK; Crizotinib; Lung cancer; NSCLC; Pemetrexed

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CROSS RESISTANCE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALK; CRIZOTINIB; LUNG CANCER; NSCLC; PEMETREXED;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84887214611     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.06.005     Document Type: Article

References (31)

1. M. Soda, Y.L. Choi, and M. Enomoto Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
2. D.W. Kim, M.J. Ahn, and Y. Shi Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) ASCO Meeting Abstracts 30 15 suppl 2012 (abstract 7533)
3. E.L. Kwak, Y.J. Bang, and D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
4. A.T. Shaw, D.W. Kim, and K. Nakagawa Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
5. C. Shih, V.J. Chen, and L.S. Gossett LY231514, a pyrrolo[2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Res 57 1997 1116 1123
6. L.G. Mendelsohn, C. Shih, and V.J. Chen Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis Semin Oncol 26 2 suppl 6 1999 42 47
7. D.R. Camidge, and R.C. Doebele Treating ALK-positive lung cancer-early successes and future challenges Nat Rev Clin Oncol 9 2012 268 277
8. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
9. G. Scagliotti, N. Hanna, and F. Fossella The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies Oncologist 14 2009 253 263
10. D.R. Camidge, S.A. Kono, and X. Lu Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed J Thorac Oncol 6 2011 774 780
11. J.O. Lee, T.M. Kim, and S.H. Lee Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer J Thorac Oncol 6 2011 1474 1480
12. A.T. Shaw, B.Y. Yeap, and M. Mino-Kenudson Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
13. O.A. O'Connor, S. Horwitz, and P. Hamlin Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies J Clin Oncol 27 2009 4357 4364
14. F.E. Boccalatte, C. Voena, and C. Riganti The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL Blood 113 2009 2776 2790
15. D.R. Gandara, E. Huang, and S. Desai Thymidylate synthase (TS) gene expression in patients with ALK positive (+) non-small cell lung cancer (NSCLC): implications for therapy ASCO Meeting Abstracts 30 15 suppl 2012 (abstract 7582)
16. A.B. Pilling, A.T. Le, and A. Tan ALK-driven lung cancer: potential therapeutic strategies for treatment and prevention of drug resistance AACR Annual Meeting Abstracts 2012 (abstract 5594)
17. D.R. Camidge, Y. Bang, and E.L. Kwak Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 2012 1011 1019
18. D.R. Camidge, S.A. Kono, and A. Flacco Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment Clin Cancer Res 16 2010 5581 5590
19. M. Varella-Garcia, Y. Cho, and X. Lu ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC) ASCO Meeting Abstracts 28 15 suppl 2010 (abstract 10533)
20. L.T. Tanoue, and F.C. Detterbeck New TNM classification for non-small-cell lung cancer Expert Rev Anticancer Ther 9 2009 413 423
21. D.B. Costa, S. Kobayashi, and S.S. Pandya CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib J Clin Oncol 29 2011 e443 e445
22. A.J. Weickhardt, B. Scheier, and J.M. Burke Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer J Thorac Oncol 7 2012 1807 1814
23. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
24. E.W. Lee, and D. Amato Cox-Type Regression Analysis for Large Numbers of Small Groups of Correlated Failure Time Observations 1992 Kluwer Academic Publishers Dordrect, Netherlands
25. G. Scagliotti, D.W. Kim, and A.T. Shaw A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ) ASCO Meeting Abstracts 30 15 suppl 2012 (abstract 7599)
26. P. Ceppi, M. Volante, and S. Saviozzi Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase Cancer 107 2006 1589 1596
27. A.T. Shaw, A.M. Varghese, and B.J. Solomon Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer Ann Oncol 24 2013 59 66
28. T. Uemura, T. Oguri, and H. Ozasa ABCC11/MRP8 confers pemetrexed resistance in lung cancer Cancer Sci 101 2010 2404 2410
29. R. Katayama, A.T. Shaw, and T.M. Khan Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers Sci Transl Med 4 2012 120ra17
30. R.C. Doebele, A.B. Pilling, and D.L. Aisner Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer Clin Cancer Res 18 2012 1472 1482
31. A. Bearz, I. Garassino, and M. Tiseo Activity of pemetrexed on brain metastases from Non-small cell lung cancer Lung Cancer 68 2010 264 268